Costas K. Yannakou

Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021

Benjamin W. Teh, Daniel K. Yeoh, Gabrielle M. Haeusler et al. · Internal Medicine Journal · 2021 · 85 citations

Pharmacy, Pharmacotherapy, Antimicrobial Pharmacotherapy +16

Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

Sikander Ailawadhi, Zi Chen, Bo Huang et al. · Clinical Cancer Research · 2023 · 38 citations · Full text

Medicine, Oncology, Pharmacology +17

Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy

Lucy C. Fox, Costas K. Yannakou, Georgina L. Ryland et al. · International Journal of Molecular Sciences · 2018 · 26 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma

Pietro R Di Ciaccio, Mark N. Polizzotto, Kate Cwynarski et al. · Blood · 2023 · 26 citations · Full text

Medicine, Hematology, Oncology +15

First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).

Sikander Ailawadhi, Asher Chanan‐Khan, Zi Chen et al. · Journal of Clinical Oncology · 2021 · 24 citations

Medicine, Oncology, Pharmacology +6